Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Published:2015-07 Issue: Volume: Page:3435
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Goláň Lubor,Goker-Alpan Ozlem,Holida Myrl,Kantola Ikka,Klopotowski Mariusz,Kuusisto Johanna,Linhart Aleš,Musial Jacek,Nicholls Kathleen,Gonzalez Rodríguez Derlis,Sharma Reena,Vujkovac Bojan,Chang Peter,Wijatyk Anna

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan;Molecular Genetics and Metabolism Reports;2024-09

2. Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations;Genes;2023-12-26

3. Late-onset and classic phenotypes of Fabry disease in males with theGLA-Thr410Ala mutation;Open Heart;2023-03

4. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process;Drugs in R&D;2021-09-20

5. Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies;Advances in Pharmacological and Pharmaceutical Sciences;2021-05-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP